POLYXENI DELAPORTA

Dr. POLYXENI DELAPORTA


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AKAikaterini Kanavaki
Aikaterini Kanavaki
KSKonstantinos Spengos
Konstantinos Spengos
MMMaria Moraki
Maria Moraki
PDPOLYXENI DELAPORTA
POLYXENI DELAPORTA
CKCatherine Kariyannis
Catherine Kariyannis
Antonis KattamisAntonis Kattamis
Antonis Kattamis
Patients with non-transfusion-dependent thalassemia (NTDT) are at risk of developing brain ischemia. Transcranial Doppler (TCD) has been established as a useful screening tool of cerebrovascular disease in patients with sickle cell disease. Proteins neuron specific enolase (NSE) and S100B are biomarkers that reflect CNS injury. The purpose of this study is to evaluate cerebral vessel vasculopathy and brain damage in NTDT patients using non-invasive methods as TCD and measurement serum levels of NSE and S100B. We included in our study 30 patients with NTDT, aged between 8 and 62 years old (mean: 29.4, median: 32) who presented in our Unit for regular follow-up. We performed in all patients a non-imaging TCD examination and have measured serum S100, NSE and lactate dehydrogenase (LDH) levels. We investigated the possible correlation between TCD results and S100B, NSE and LDH levels as well as between NSE-LDH and S100B-LDH levels by regression analysis. We found a statistically significant relationship for both NSE, S100B with LDH. We also found a statistically significant relationship for S100B and time-averaged mean velocity (TAMV)/peak velocity of left middle cerebral artery (MCA), NSE and pulsatility index (PI)/resistive index (RI) of the left posterior cerebral artery (PCA). TCD results correlated with biomarkers for brain ischemia. This finding enhances the role of TCD as a screening tool for brain ischemia in patients with NTDT.

17 August 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
PDPOLYXENI DELAPORTA
POLYXENI DELAPORTA
CSChristalena Sofocleous
Christalena Sofocleous
ESEftichia Stiakaki
Eftichia Stiakaki
SPSophia Polychronopoulou
Sophia Polychronopoulou
MEMarina Economou
Marina Economou
AKAntonis Kattamis
Antonis Kattamis

11 March 2022 in Biology
Verified
Journal Article
Open access
PDF file
CKChristos Kattamis
Christos Kattamis
MSMyrto Skafida
Myrto Skafida
PDPOLYXENI DELAPORTA
POLYXENI DELAPORTA
CVChristina Vrettou
Christina Vrettou
JTJan Traeger-Synodinos
Jan Traeger-Synodinos
Antonis KattamisAntonis Kattamis
Antonis Kattamis
The Corfu δ0β+ thalassemic allele is a unique thalassemic allele consisting of the simultaneous presence in cis of a deletion of the δ-globin (Hemoglobin Subunit Delta, HBD) and a single nucleotide variant in the β-globin gene (Hemoglobin Subunit Beta, HBB). The allele has, so far, been described in individuals of Greek origin. The objectives of the study are to ascertain the prevalence of the Corfu δ0β+ allele in comparison to other β-thalassemia variants encountered in Greece using our in-house data repository of 2558 β-thalassemia heterozygotes, and to evaluate the hematological phenotype of Corfu δ0β+ heterozygotes in comparison to heterozygotes with the most common β+- and deletion α0- thalassemia variants in Greece. The results of the study showed a relative incidence of heterozygotes with Corfu δ0β+ at 1.56% of all β-thalassemic alleles, and a distinct hematological phenotype of the heterozygotes characterized by microcytic, hypochromic anemia with normal levels of HbA2 (Hemoglobin A2) and elevated HbF (Hemoglobin F) levels. The application of a specific methodology for the identification of the Corfu δ0β+ allele is important for precise prenatal and antenatal diagnosis programs in Greece.